High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma.
ADP-ribosyl Cyclase 1
/ metabolism
Adult
Aged
Aged, 80 and over
B-Lymphocytes
/ immunology
Bone Marrow
/ immunology
Clonal Anergy
Down-Regulation
Female
Flow Cytometry
Humans
Lymphoma, Large B-Cell, Diffuse
/ immunology
Male
Membrane Glycoproteins
/ metabolism
Middle Aged
Prognosis
Receptors, Complement 3d
/ metabolism
Regression Analysis
Survival Analysis
Anergic
B cells
Diffuse large B cell lymphoma
Microenvironment
Prognosis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Nov 2020
03 Nov 2020
Historique:
received:
30
04
2020
accepted:
14
10
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
20
4
2021
Statut:
epublish
Résumé
Diffuse large B cell lymphoma (DLBCL) is the commonest lymphoma that is highly aggressive where one-third of the patients relapse despite effective treatment. Interaction between the lymphoma cells and the non-clonal immune cells within the bone marrow microenvironment is thought to play a critical role in the pathogenesis of DLBCL. We used flow cytometry to characterize the proportion of B cell subpopulations in the bone marrow (N = 47) and peripheral blood (N = 54) of 75 DLBCL patients at diagnosis and study their impact on survival. Anergic B cells in the bone marrow (BM), characterized as having CD21(-/low)/CD38- expression, influenced survival with high numbers (defined as > 13.9%) being associated with significantly shorter overall survival (59.7 months vs 113.6 months, p = 0.0038). Interestingly, low numbers of anergic B cells in the BM (defined as ≤13.9%) was associated with germinal center B cell type of DLBCL (p = 0.0354) that is known to have superior rates of survival when compared to activated B cell type. Finally, Cox regression analysis in our cohort of patients established that the inferior prognosis of having high numbers of anergic B cells in the bone marrow was independent of the established Revised International Prognostic Index (R-IPI) score. High proportion of anergic B cells in the BM characterized by CD21(-/low)/CD38- expression predicts poor survival outcomes in DLBCL.
Sections du résumé
BACKGROUND
BACKGROUND
Diffuse large B cell lymphoma (DLBCL) is the commonest lymphoma that is highly aggressive where one-third of the patients relapse despite effective treatment. Interaction between the lymphoma cells and the non-clonal immune cells within the bone marrow microenvironment is thought to play a critical role in the pathogenesis of DLBCL.
METHODS
METHODS
We used flow cytometry to characterize the proportion of B cell subpopulations in the bone marrow (N = 47) and peripheral blood (N = 54) of 75 DLBCL patients at diagnosis and study their impact on survival.
RESULTS
RESULTS
Anergic B cells in the bone marrow (BM), characterized as having CD21(-/low)/CD38- expression, influenced survival with high numbers (defined as > 13.9%) being associated with significantly shorter overall survival (59.7 months vs 113.6 months, p = 0.0038). Interestingly, low numbers of anergic B cells in the BM (defined as ≤13.9%) was associated with germinal center B cell type of DLBCL (p = 0.0354) that is known to have superior rates of survival when compared to activated B cell type. Finally, Cox regression analysis in our cohort of patients established that the inferior prognosis of having high numbers of anergic B cells in the bone marrow was independent of the established Revised International Prognostic Index (R-IPI) score.
CONCLUSIONS
CONCLUSIONS
High proportion of anergic B cells in the BM characterized by CD21(-/low)/CD38- expression predicts poor survival outcomes in DLBCL.
Identifiants
pubmed: 33143694
doi: 10.1186/s12885-020-07525-6
pii: 10.1186/s12885-020-07525-6
pmc: PMC7641859
doi:
Substances chimiques
Membrane Glycoproteins
0
Receptors, Complement 3d
0
CD38 protein, human
EC 3.2.2.5
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061Références
Int J Cancer. 2014 Nov 1;135(9):2146-56
pubmed: 24639369
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
Eur J Haematol. 2013 Aug;91(2):122-8
pubmed: 23679234
Blood. 2010 Jun 17;115(24):5026-36
pubmed: 20231422
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13451-6
pubmed: 19666505
Int J Hematol. 2018 Sep;108(3):254-266
pubmed: 29748856
Histopathology. 2011 Jan;58(1):69-80
pubmed: 21261684
Blood. 2006 Jan 1;107(1):265-76
pubmed: 16150940
Clin Exp Immunol. 2016 Aug;185(2):252-62
pubmed: 27010233
Blood. 2011 May 19;117(20):5425-37
pubmed: 21421840
Nature. 1988 Aug 25;334(6184):676-82
pubmed: 3261841
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
J Clin Oncol. 2005 Aug 1;23(22):5027-33
pubmed: 15955905
Am J Clin Pathol. 2012 May;137(5):805-14
pubmed: 22523221
Pathol Oncol Res. 2016 Jul;22(3):567-77
pubmed: 26750138
Leuk Lymphoma. 2008 May;49(5):959-64
pubmed: 18464115
Proc Natl Acad Sci U S A. 1982 Mar;79(6):2013-7
pubmed: 6804951
Arthritis Rheum. 2013 Apr;65(4):1085-96
pubmed: 23279883
Blood. 2013 May 9;121(19):3879-88, S1-8
pubmed: 23460614
Egypt J Immunol. 2011;18(2):23-30
pubmed: 23082467
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2005 Jun 1;105(11):4390-8
pubmed: 15701725
Blood. 2014 May 22;123(21):3214-5
pubmed: 24855189
N Engl J Med. 2010 Apr 15;362(15):1417-29
pubmed: 20393178
Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):83-88
pubmed: 28027895
Histopathology. 2008 Feb;52(3):340-7
pubmed: 18269585
Am J Clin Pathol. 2015 Dec;144(6):935-44
pubmed: 26573001
Haematologica. 2015 Feb;100(2):238-45
pubmed: 25381134
Leukemia. 2011 Sep;25(9):1502-9
pubmed: 21606957
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
Oncotarget. 2017 Jul 18;8(29):47790-47800
pubmed: 28548962
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Scand J Immunol. 2015 Sep;82(3):254-61
pubmed: 26119182
Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):534-542
pubmed: 26862953
Immunol Rev. 1998 Apr;162:247-59
pubmed: 9602369
Science. 1970 Sep 11;169(3950):1042-9
pubmed: 4194660
Blood. 2009 Oct 15;114(16):3367-75
pubmed: 19636060
Blood. 2010 Jan 21;115(3):519-29
pubmed: 19965666
Nat Rev Immunol. 2015 Mar;15(3):191-7
pubmed: 25656707
Nat Rev Cancer. 2014 Aug;14(8):517-34
pubmed: 25008267
Blood. 2010 Jun 17;115(24):4976-8
pubmed: 20558622
Hematol Oncol. 2015 Mar;33(1):42-7
pubmed: 24470400
Biochim Biophys Acta. 2016 Mar;1863(3):471-482
pubmed: 26554850
J Immunol. 2009 May 15;182(10):5982-93
pubmed: 19414749
Eur J Haematol. 2010 Nov;85(5):405-15
pubmed: 20662897
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
J Clin Oncol. 2010 May 10;28(14):2373-80
pubmed: 20385988
Virchows Arch. 2014 Feb;464(2):229-39
pubmed: 24306958
Pathology. 2007 Dec;39(6):580-5
pubmed: 18027262
Eur J Haematol. 2014 Mar;92(3):204-10
pubmed: 24283206